| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/EURHEARTJ/EHV588 |
| P698 | PubMed publication ID | 26543046 |
| P50 | author | Luis Miguel Ruilope | Q56550076 |
| Dirk J van Veldhuisen | Q82060328 | ||
| P2093 | author name string | Alan S Maisel | |
| Kevin Damman | |||
| P2860 | cites work | A new equation to estimate glomerular filtration rate | Q24651973 |
| Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status | Q27015422 | ||
| Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction | Q28213597 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data | Q30714179 | ||
| Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial | Q33511925 | ||
| Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. | Q33793198 | ||
| Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure | Q33799444 | ||
| Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men. | Q34008962 | ||
| Blood urea nitrogen and serum creatinine: not married in heart failure | Q43266279 | ||
| Albuminuria in chronic heart failure: prevalence and prognostic importance | Q43291306 | ||
| Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure | Q43807471 | ||
| Tubular damage and worsening renal function in chronic heart failure | Q43979582 | ||
| Regulation of glomerular filtration rate in chronic congestive heart failure patients | Q44463850 | ||
| Proenkephalin and prognosis after acute myocardial infarction | Q44538374 | ||
| Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction | Q44556884 | ||
| Measurement of renal function in kidney donors using serum cystatin C and beta(2)-microglobulin | Q44663244 | ||
| Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function | Q44854902 | ||
| Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin | Q45173397 | ||
| The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure | Q45768858 | ||
| Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial | Q46274105 | ||
| Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure | Q46356815 | ||
| Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery | Q46423060 | ||
| The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. | Q46677502 | ||
| Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. | Q48278579 | ||
| Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. | Q48461319 | ||
| Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study | Q48680598 | ||
| Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure | Q48852531 | ||
| Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome | Q48946641 | ||
| Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. | Q50985608 | ||
| The impact of renal tubular damage, as assessed by urinary β2-microglobulin-creatinine ratio, on cardiac prognosis in patients with chronic heart failure. | Q50993823 | ||
| Renal function largely influences Galectin-3 prognostic value in heart failure. | Q50995380 | ||
| Clinical outcome of renal tubular damage in chronic heart failure. | Q51451420 | ||
| Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. | Q51582580 | ||
| Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. | Q51932219 | ||
| Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. | Q52020788 | ||
| Renal function, neurohormonal activation, and survival in patients with chronic heart failure. | Q52076638 | ||
| The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. | Q52081068 | ||
| Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. | Q53090641 | ||
| Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. | Q54426460 | ||
| Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis | Q34380599 | ||
| Renal function: the Cinderella of cardiovascular risk profile | Q34459987 | ||
| Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study | Q34489305 | ||
| Dual action of neutrophil gelatinase-associated lipocalin | Q34603152 | ||
| Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction | Q34633271 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| The role of the kidney in heart failure | Q34641418 | ||
| A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure | Q34937242 | ||
| Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure | Q35017352 | ||
| Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis | Q35070734 | ||
| Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial | Q35128552 | ||
| Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. | Q35662925 | ||
| The kidney in heart failure: an update | Q35737499 | ||
| Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure | Q36093457 | ||
| Diuretic strategies in patients with acute decompensated heart failure | Q36141962 | ||
| Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure | Q36178412 | ||
| Association between systemic neutrophil gelatinase-associated lipocalin and anemia, relative hypochromia, and inflammation in chronic systolic heart failure | Q36281136 | ||
| Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate | Q36344899 | ||
| Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. | Q36522700 | ||
| Ultrafiltration in decompensated heart failure with cardiorenal syndrome | Q36949209 | ||
| Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure | Q37194692 | ||
| Urinary C-type natriuretic peptide: a new heart failure biomarker. | Q37302127 | ||
| Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion | Q37480335 | ||
| Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis | Q37619895 | ||
| Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure | Q37693315 | ||
| Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure | Q37781139 | ||
| Urinary proteins in heart failure | Q38028671 | ||
| Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction | Q38181037 | ||
| Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospital | Q38440582 | ||
| Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. | Q39835614 | ||
| Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CH | Q40097815 | ||
| Cystatin-C and mortality in elderly persons with heart failure. | Q40454237 | ||
| Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction | Q40875896 | ||
| Urine Biomarkers Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) Have Different Patterns in Heart Failure Exacerbation | Q42134856 | ||
| Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization | Q42202790 | ||
| Terminology and definition of changes renal function in heart failure. | Q42686685 | ||
| Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients | Q43178283 | ||
| P433 | issue | 33 | |
| P921 | main subject | heart failure | Q181754 |
| biomarker | Q864574 | ||
| P304 | page(s) | 2577-2585 | |
| P577 | publication date | 2015-11-04 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure | |
| P478 | volume | 37 |
| Q28066260 | Acute kidney injury 2016: diagnosis and diagnostic workup |
| Q91458118 | B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure |
| Q26768192 | Biomarkers in heart failure with preserved ejection fraction |
| Q48165505 | Blood Urea Nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU. |
| Q89840302 | Clinical importance of urinary sodium excretion in acute heart failure |
| Q30235456 | Complications during pregnancy and fetal development: implications for the occurrence of chronic kidney disease |
| Q56990072 | Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? |
| Q53282871 | Diuretics in cardiorenal syndrome: what's new? |
| Q53122864 | Drugs and the Kidneys: Clinical Pharmacology Perspectives. |
| Q90416607 | Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction |
| Q92458947 | Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology |
| Q41712447 | Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition. |
| Q89539978 | Intravascular Volume Modulates the Outcome Predictive Capacity of Clinical Renal Function Biomarkers in Clinically "Euvolemic" Chronic Heart Failure Patients |
| Q87743396 | Letter by Brzezinski et al Regarding Article, "Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study" |
| Q55079780 | Miniaturized Bio-and Chemical-Sensors for Point-of-Care Monitoring of Chronic Kidney Diseases. |
| Q92623491 | Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system |
| Q40126626 | Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure |
| Q40052970 | Predictors of Acute Renal Injury Study (PARIS) among HIV-positive individuals: design and methods |
| Q41166002 | Prognostic Significance of Interleukin-34 (IL-34) in Patients With Chronic Heart Failure With or Without Renal Insufficiency |
| Q47438578 | Real-Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. |
| Q52364966 | Redefining biomarkers in heart failure. |
| Q51822693 | Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. |
| Q42650180 | Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial |
| Q50235218 | Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition |
| Q46833198 | Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? |
| Q37696493 | Variability of biomarkers in patients with chronic heart failure and healthy controls |
Search more.